CCI approves Kotak Special Situations Fund's proposed investment in Biocon’s arm

14 Aug 2023 Evaluate

The Competition Commission of India (CCI) has approved Kotak Special Situations Fund's (KSSF) proposed investment in Biocon’s subsidiary -- Biocon Biologics under the green channel route. The investment will help Biocon Biologics' acquisition of the biosimilars business of its partner Viatris. KSSF is a Sebi-registered alternative investment fund (AIF).

The combination relates to the acquirer (KSSF) proposing to purchase certain equity shares in the target (Biocon Biologics). Under the green channel route, a transaction which does not raise any risk of an appreciable adverse effect on competition is deemed to be approved on being intimated to the anti-trust regulator.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


Biocon Share Price

311.55 0.80 (0.26%)
15-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1528.20
Dr. Reddys Lab 5872.35
Cipla 1405.95
Zydus Lifesciences 997.45
Lupin 1638.40
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.